Mi-Kyung Kim
Dr. Mi-Kyung Kim has served as a Vice President, leading the overall new drug discovery research for metabolic and immune-mediated diseases at Dong-A ST. She has more than 25 years of experience in the pharmaceutical industry. She has a high level of understanding of new drug development, experiencing both domestic and global clinical development, as well as overall new drug development from initial drug discovery to new drug approval while leading the project. She has specialized research experience focusing on chronic endocrine/cardiometabolic disease era such as diabetes, obesity, NASH, chronic kidney disease and osteoporosis. During her career at Dong-A, she has led numerous projects, including a novel dipeptidyl peptidase inhibitor (evogliptin, Suganon®), which became the world ninth approved product for the treatment of type 2 diabetes. DA-1241 and DA-1726 are new drug candidates for metabolic diseases, and she has been establishing drug evaluation and development strategies while establishing the concept of drugs from the initial target selection stage of these two projects to the present. Academically, after she graduated from the College of Pharmacy at Ewha Womans University in Korea, she studied cancer metastasis and beta cell biology/proteomics in the same graduate school.